Table 1.
Effect of atorvastatin therapy on CRP concentrations in 2,322 patients with type 2 diabetes
| Intention-to-treat analysis | Placebo (n = 1,148) |
Atorvastatin (n = 1,174) |
|---|---|---|
| CRP, nmol/l [mg/l] | ||
| Baseline, median (25th, 75th percentile) | 14.5 (5.8, 33.8) [1.5 (0.6, 3.6)] |
12.6 (5.9, 29.4) [1.3 (0.6, 3.1)] |
| 12 months, median (25th, 75th percentile) | 17.2 (8.0, 39.2) [1.8 (0.8, 4.1)] |
11.9 (5.1, 27.3) [1.2 (0.5, 2.9)] |
| Change, % median (25th, 75th percentile) | 18.5 (−41.4, 204.8) | −9.8 (−56.5, 115.2) |
| Net treatment effect | ||
| ANCOVA using log-transformed CRP values, % difference in CRP compared with placebo (95% CI) | ||
| Model 1a | −29.9 (−35.9, −23.3)* | |
| Model 2b | −32.0 (−40.4, −22.4)* | |
| ANCOVA using median regression of untransformed CRP values, absolute difference in CRP compared with placebo (95% CI) | ||
| Model 1a, nmol/l [mg/l] | −4.9 (−6.1, −3.8) [−0.5 (−0.6, −0.4)]* |
|
| Model 2b, nmol/l [mg/l] | −4.4 (−6.4, −2.3) [−0.5 (−0.7, −0.2)]* |
|
aModel 1, age and sex
bModel 2, race, smoking status, systolic blood pressure, BMI, HbA1c, change in LDL-cholesterol, days between randomisation and CRP measurement; this model is based on 2,311 participants with complete covariate data
*p < 0.0001 vs placebo